The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Momelotinib in 2024: how should this agent be used in MF with anemia?
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, comments on the role of momelotinib in the treatment landscape of myelofibrosis (MF). The agent is approved for patients with MF and anemia; however, Dr Kuykendall highlights that it is unclear whether using the agent in the frontline or in the second line following prior ruxolitinib exposure is better. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Celgene/BMS, Cogent, Incyte, Abbvie, Imago, Novartis, PharmaEssentia, CTI Biopharma, MorphoSys, GSK, Karyopharm; Research Funding: MorphoSys, BMS, Protagonist Therapeutics, Janssen; Advisory Board: Dark Blue Therapeutics.
